Chemomab Therapeutics Competitors

Chemomab Therapeutics (NASDAQ:CMMB) and Longboard Pharmaceuticals (NASDAQ:LBPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.

Profitability

This table compares Chemomab Therapeutics and Longboard Pharmaceuticals' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Chemomab Therapeutics and Longboard Pharmaceuticals' gross revenue, earnings per share and valuation.

Analyst Ratings

This is a summary of recent ratings and price targets for Chemomab Therapeutics and Longboard Pharmaceuticals, as provided by MarketBeat.com.

Chemomab Therapeutics presently has a consensus target price of $42.00, suggesting a potential upside of 141.24%. Longboard Pharmaceuticals has a consensus target price of $32.75, suggesting a potential upside of 281.70%. Given Longboard Pharmaceuticals' higher probable upside, analysts clearly believe Longboard Pharmaceuticals is more favorable than Chemomab Therapeutics.

Summary

Longboard Pharmaceuticals beats Chemomab Therapeutics on 2 of the 2 factors compared between the two stocks.

Chemomab Therapeutics (NASDAQ:CMMB) and ImmunoPrecise Antibodies (NASDAQ:IPA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk and institutional ownership.

Profitability

This table compares Chemomab Therapeutics and ImmunoPrecise Antibodies' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Chemomab Therapeutics and ImmunoPrecise Antibodies' gross revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Chemomab Therapeutics and ImmunoPrecise Antibodies, as provided by MarketBeat.

Chemomab Therapeutics presently has a consensus target price of $42.00, suggesting a potential upside of 141.24%. Given Chemomab Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Chemomab Therapeutics is more favorable than ImmunoPrecise Antibodies.

Summary

Chemomab Therapeutics beats ImmunoPrecise Antibodies on 3 of the 3 factors compared between the two stocks.

Chemomab Therapeutics (NASDAQ:CMMB) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk and institutional ownership.

Profitability

This table compares Chemomab Therapeutics and Gain Therapeutics' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Chemomab Therapeutics and Gain Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Chemomab Therapeutics and Gain Therapeutics, as provided by MarketBeat.

Chemomab Therapeutics presently has a consensus target price of $42.00, suggesting a potential upside of 141.24%. Gain Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 206.44%. Given Gain Therapeutics' higher probable upside, analysts plainly believe Gain Therapeutics is more favorable than Chemomab Therapeutics.

Summary

Gain Therapeutics beats Chemomab Therapeutics on 2 of the 2 factors compared between the two stocks.

Chemomab Therapeutics (NASDAQ:CMMB) and Evaxion Biotech A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk and institutional ownership.

Profitability

This table compares Chemomab Therapeutics and Evaxion Biotech A/S's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Chemomab Therapeutics and Evaxion Biotech A/S's gross revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Chemomab Therapeutics and Evaxion Biotech A/S, as provided by MarketBeat.

Chemomab Therapeutics presently has a consensus target price of $42.00, suggesting a potential upside of 141.24%. Evaxion Biotech A/S has a consensus target price of $18.00, suggesting a potential upside of 239.62%. Given Evaxion Biotech A/S's higher probable upside, analysts plainly believe Evaxion Biotech A/S is more favorable than Chemomab Therapeutics.

Summary

Evaxion Biotech A/S beats Chemomab Therapeutics on 2 of the 2 factors compared between the two stocks.

Chemomab Therapeutics (NASDAQ:CMMB) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk and institutional ownership.

Profitability

This table compares Chemomab Therapeutics and Longeveron's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Chemomab Therapeutics and Longeveron's gross revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Chemomab Therapeutics and Longeveron, as provided by MarketBeat.

Chemomab Therapeutics presently has a consensus target price of $42.00, suggesting a potential upside of 141.24%. Given Chemomab Therapeutics' higher probable upside, analysts plainly believe Chemomab Therapeutics is more favorable than Longeveron.

Summary

Chemomab Therapeutics beats Longeveron on 2 of the 2 factors compared between the two stocks.

Viridian Therapeutics (NASDAQ:VRDN) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

Profitability

This table compares Viridian Therapeutics and Chemomab Therapeutics' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Viridian Therapeutics and Chemomab Therapeutics' revenue, earnings per share and valuation.

Analyst Recommendations

This is a breakdown of current recommendations for Viridian Therapeutics and Chemomab Therapeutics, as reported by MarketBeat.com.

Viridian Therapeutics currently has a consensus price target of $34.00, suggesting a potential upside of 94.06%. Chemomab Therapeutics has a consensus price target of $42.00, suggesting a potential upside of 141.24%. Given Chemomab Therapeutics' higher probable upside, analysts plainly believe Chemomab Therapeutics is more favorable than Viridian Therapeutics.